目的探討丹參酮ⅡA磺酸鈉聯(lián)合依達拉奉治療急性腦梗死的臨床療效及安全性。方法選取100例急性腦梗死患者,隨機數(shù)字表法分為兩組,對照組患者（50例）給予依達拉奉治療,觀察組患者（50例）給予丹參酮ⅡA磺酸鈉聯(lián)合依達拉奉治療,均治療14 d。觀察并記錄兩組患者治療后1個月的療效,治療前后ESS評分、SF-36評分及治療期間不良反應情況。結果治療后,觀察組有效率為90.0%,對照組有效率為72.0%,觀察組治療有效率明顯高于對照組（P<0.05）。與治療前相比,治療后兩組ESS評分均明顯增加（P<0.05）,且觀察組在治療3、7、14 d的ESS評分均明顯高于對照組（P<0.05）。治療前兩組SF-36各項得分相比,差異沒有統(tǒng)計學意義；治療后,兩組SF-36各項得分均明顯升高（P<0.05）,且觀察組在生理功能、生理職能及精神健康上的評分高于對照組（P<0.05）。治療期間,兩組不良反應率無明顯差異。結論丹參酮ⅡA磺酸鈉聯(lián)合依達拉奉對急性腦梗死具有較好的治療作用,能改善患者神經(jīng)功能,提高患者生活質(zhì)量,用藥具有安全性,值得臨床推廣使用。

Objective To discuss the efficacy and safety of sodium tanshinone ⅡA combined with edaravone in treatment of acute cerebral infarction. Methods 100 cases of acute cerebral infarction were randomly divided into two groups. The control group (50 cases) was treated with edaravone. The observation group (50 cases) was treated with sodium tanshinone ⅡA combined with edaravone. The efficacy of sodium tanshinone ⅡA combined with edaravone in treatment of acute cerebral infarction was evaluated by the efficacy at 1 month after treatment, ESS scores, SF-36 scores before and after treatment and adverse reaction during treatment. Results After treatment, the effective rate of observation group was 90.0% and control group was 72.0%. The effective rate of observation group was higher than that of the control group (P < 0.05). Compared with the value before treatment, the ESS scores of two groups were increased after treatment (P < 0.05). 3 d, 7 d, 14 d after treatment, the ESS scores of observation group was higher than that of the control group (P < 0.05). Before treatment, there were no statistical significance on SF-36 between two groups. After treatment, the SF-36 scores were increased in two groups (P < 0.05). During treatment, there were no statistical significance on adverse reaction between two groups. Conclusion Sodium tanshinone ⅡA combined with edaravone had a good therapeutic effect on acute cerebral infarction. It could improve the quality of life and neurological function with high safety. It was worthy of clinical application.